Global Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Opportunities, And Trends By Treatment Type (Drug Class, Oxygen Therapy, Lung Transplant, Others), By Drug Type (Pirfenidone, Nintedanib), By Application (Hospital, Clinic), And By Geography - Forecasts From 2024 To 2029

  • Published : Feb 2024
  • Report Code : KSI061612250
  • Pages : 114

The Idiopathic pulmonary fibrosis market is evaluated at US$3.459 billion for the year 2022 growing at a CAGR of 11.87% reaching the market size of US$7.585 billion by the year 2029.

Idiopathic pulmonary fibrosis is a certain type of severe lung disease. Idiopathic pulmonary fibrosis is a lung disease in which the lung tissues are damaged by the formation of scar tissue within the lungs. The scar tissue is formed at the edges of the lungs, and they are spread to the center of the lungs. In this disease condition, normal tissues are replaced by the scar tissues formed in the lungs. The heavy and rough nature of scar tissue formed in the lungs will result in heavy and rough breathing in people. Idiopathic pulmonary fibrosis lung disease will result in the reduction of the oxygen capacity of the lungs, making the disease more severe and critical. A specific cause is not at all identified in the case of idiopathic pulmonary fibrosis, but smoking cigarettes and exposure to polluted and toxic air are major factors leading to the disease. The increasing rate of the disease reported around the globe is raising the risk and criticality of the disease. The fewer treatment methods available for Idiopathic pulmonary fibrosis also increase the risk factor and fatal rate of lung disease.

The increasing pollution rate and rising trend of smoking addiction are giving potential to the market growth of Idiopathic pulmonary fibrosis treatment on the global medical market. The low availability of proper medication and treatment for Idiopathic pulmonary fibrosis is also driving the market growth of global idiopathic pulmonary fibrosis treatment. The global idiopathic pulmonary fibrosis (IPF) treatment market is expected to grow due to increasing prevalence, medical research advancements, and innovative therapies. The market is characterized by ongoing initiatives to address unmet medical needs, introducing novel therapeutic options, and focusing on improving patient outcomes.

MARKET DRIVERS:

  • The rising rate of smoking and air pollution is anticipated to surge the market growth

The exact cause or reasons are not recorded in the case of Idiopathic pulmonary fibrosis lung disease. The increasing smoking habit in people is considered one of the major reasons for the cause of Idiopathic pulmonary fibrosis. Smoking cigarettes adversely affects the natural breathing capacity and lung health of people. The decreased lung capacity and the health of the lungs are making individuals more vulnerable to lung diseases. The reports of the WHO (World Health Organisation) claim that about 15 of every 100 men are cigarette smokers, and it's approximately 15.3%. In the case of smoking habits in women, about 13 of every 100 women are also smokers. The U.S. Department of Health and Human Services states that in America, cigarette smoking is highest among people in the age group 25 to 44 years and 45 to 64 years.

Air pollution is one of the major impacts caused as a result of industrialization. The large emissions from factories and production plants contribute to a major share of atmospheric pollution. The higher rate of carbon emission from automobiles is also leading to rising air pollution in the atmosphere. The increasing air pollution in the atmosphere is also causing lung diseases and declining lung health in people, making them vulnerable to severe lung diseases like idiopathic pulmonary fibrosis. The increased smoking rate and air pollution are giving potential to the market growth of Idiopathic Pulmonary Fibrosis treatment.

  • An increasing rate of an aging population will bolster the growth of the market.

The increasing rate of an aging population is also a significant factor driving the market growth of the pulmonary fibrosis treatment market. The aging population or people above 60 to 65 years of age are more prone to the diseases like idiopathic pulmonary fibrosis. Idiopathic pulmonary Fibrosis and lung diseases are also becoming more fatal and critical in aged people resulting in mortality. The low availability of proper medication and increasing cases of idiopathic pulmonary fibrosis are driving the market growth of the global idiopathic pulmonary fibrosis treatment market. The aging population is increasingly utilizing healthcare resources, leading to a growing demand for specialized care, particularly for chronic diseases like idiopathic pulmonary fibrosis. Advancements in medical diagnostics and increased awareness may increase early and accurate diagnoses, leading to a higher demand for appropriate treatments. This recognition of idiopathic pulmonary fibrosis as a significant health concern may drive research and development efforts to discover and commercialize innovative treatment options.

Asia Pacific region is predicted to hold a significant market share

Asia Pacific region is having more market growth in idiopathic pulmonary fibrosis treatment. The rising number of lung patients and people suffering from Idiopathic Pulmonary Fibrosis in the Asia Pacific region is raising the market growth of idiopathic pulmonary Fibrosis treatment in Asia. The large investments made in the medication sector are also boosting market growth. The Asia Pacific region is experiencing a surge in awareness of idiopathic pulmonary fibrosis (IPF), leading to increased demand for treatments. The region's aging population, which is more common in older individuals, is also contributing to the disease's prevalence. Improvements in healthcare infrastructure and access to advanced medical treatments could improve diagnosis and treatment. Increased investment in research and development could lead to novel therapies and market share growth. Government initiatives, healthcare policies, and reimbursement programs could encourage the adoption of advanced treatments. Collaborations between pharmaceutical companies, research institutions, and healthcare providers could lead to the development and commercialization of effective IPF treatments. Patient advocacy groups can also play a role in raising awareness and influencing policies.

Key Developments:

  • January 2023- Lotus Pharmaceutical has received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, a generic version of Boehringer Ingelheim's OFEV®. The company plans to launch the generic Nintedanib Capsules at the earliest available opportunity.
  • May 2022- Sandoz has announced the launch of its first generic pirfenidone in the US for treating idiopathic pulmonary fibrosis (IPF), a rare, progressive disease primarily affecting adults over 50. The AB-rated medication is the first fully substitutable equivalent to Genentech's Esbriet and is now available through specialty pharmacies with a $0 co-pay program for eligible patients. IPF is a progressive, rare disease with no cure, affecting approximately 140,000 Americans.

Segmentation

  • By Treatment Type
    • Drug class
    • Oxygen Therapy
    • Lung Transplant
    • Others
  • By Drug Type
    • Pirfenidone
    • Nintedanib
  • By Application
    • Hospital
    • Clinic
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • UK
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

The global idiopathic pulmonary fibrosis treatment market is expected to reach a market size of US$7.585 billion by 2029.
Idiopathic Pulmonary Fibrosis Treatment Market was valued at US$3.459 billion in 2022.
The idiopathic pulmonary fibrosis treatment market is expected to grow at a CAGR of 11.87% during the forecast period.
The increasing pollution rate and rising trend of smoking addiction are giving potential to the idiopathic pulmonary fibrosis treatment market growth.
Asia Pacific region holds a significant share in the idiopathic pulmonary fibrosis treatment market owing to the rising number of lung patients and people suffering from Idiopathic Pulmonary Fibrosis in the region.

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Russia-Ukraine War Impact Analysis

5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

5.1. Introduction

5.2. Drug class

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Oxygen Therapy

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

5.4. Lung Transplant

5.4.1. Market Opportunities and Trends

5.4.2. Growth Prospects

5.4.3. Geographic Lucrativeness

5.5. Others

5.5.1. Market Opportunities and Trends

5.5.2. Growth Prospects

5.5.3. Geographic Lucrativeness

6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY DRUG TYPE

6.1. Introduction

6.2. Pirfenidone

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Nintedanib

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY APPLICATION 

7.1. Introduction

7.2. Hospital

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Clinic

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Treatment Type

8.2.2. By Drug Type

8.2.3. By Application 

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Opportunities and Trends

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Opportunities and Trends

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Opportunities and Trends

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Treatment Type

8.3.2. By Drug Type

8.3.3. By Application

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Opportunities and Trends

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Opportunities and Trends

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Opportunities and Trends

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Treatment Type

8.4.2. By Drug Type

8.4.3. By Application

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Opportunities and Trends

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Opportunities and Trends

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Opportunities and Trends

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Opportunities and Trends

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Opportunities and Trends

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Opportunities and Trends

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Treatment Type

8.5.2. By Drug Type

8.5.3. By Application

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Opportunities and Trends

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Opportunities and Trends

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Opportunities and Trends

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Treatment Type

8.6.2. By Drug Type

8.6.3. By Application

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Opportunities and Trends

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Opportunities and Trends

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Opportunities and Trends

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Opportunities and Trends

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Opportunities and Trends

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Opportunities and Trends

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Opportunities and Trends

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Opportunities and Trends

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Boehringer Ingelheim GMBH

10.2. Bristol-Myers Squibb Company

10.3. Biogen

10.4. Cipla

10.5. Hoffman-La Roche AG

10.6. Fibrogen, Inc.

10.7. Galapagos NV

10.8. Medicinova, Inc.

10.9. Novartis AG

10.10. Prometic Life sciences Inc.


Boehringer Ingelheim GMBH

Bristol-Myers Squibb Company

Biogen

Cipla

Hoffman-La Roche AG

Fibrogen, Inc.

Galapagos NV

Medicinova, Inc.

Novartis AG

Prometic Life sciences Inc.